Aurinia Pharmaceuticals (AUPH) News Today $8.21 +0.01 (+0.12%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$8.20 -0.02 (-0.18%) As of 05/2/2025 04:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Glass Lewis Recommends That Aurinia Shareholders Vote "FOR" All Proposals at 2025 Annual General MeetingMay 1 at 2:51 AM | finance.yahoo.comISS Recommends That Aurinia Shareholders Vote "FOR" All Proposals at 2025 Annual General MeetingApril 29, 2025 | uk.finance.yahoo.comAurinia Pharmaceuticals: Shareholder Pressure And Sales GrowthApril 26, 2025 | seekingalpha.comAurinia Pharmaceuticals (AUPH) to Release Quarterly Earnings on ThursdayAurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 1. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-1-aurinia-pharmaceuticals-inc-stock/)April 26, 2025 | marketbeat.comXTX Topco Ltd Takes $384,000 Position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)XTX Topco Ltd acquired a new stake in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) (TSE:AUP) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 42,754 shares of the biotechnology company's sApril 25, 2025 | marketbeat.comZacks Industry Outlook Highlights Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus TherapeuticsApril 25, 2025 | finance.yahoo.comConcerned Shareholders of Aurinia Pharmaceuticals Announce Their Intention to Withhold Support for CEO Peter Greenleaf at 2025 Annual MeetingApril 23, 2025 | businesswire.comRenaissance Technologies LLC Boosts Holdings in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)Renaissance Technologies LLC boosted its position in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) (TSE:AUP) by 44.0% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 700,900 shares of the biotechnology company's stock after purchasinApril 21, 2025 | marketbeat.comAurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Shares Purchased by Federated Hermes Inc.Federated Hermes Inc. grew its stake in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) (TSE:AUP) by 1,233,875.0% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 49,359 shares of the biotechnology company's stoApril 20, 2025 | marketbeat.comVanguard Group Inc. Purchases 112,113 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)Vanguard Group Inc. increased its position in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) (TSE:AUP) by 6.9% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 1,729,948 shares of the biotechnology compApril 20, 2025 | marketbeat.comAdvisory Services Network LLC Has $710,000 Holdings in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)Advisory Services Network LLC trimmed its position in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) (TSE:AUP) by 57.1% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 79,066 shares of the bApril 17, 2025 | marketbeat.comAurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Shares Bought by Franklin Resources Inc.Franklin Resources Inc. lifted its holdings in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) (TSE:AUP) by 358.8% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 92,921 shares of the biotechnology company's stock after acquiring anApril 17, 2025 | marketbeat.comJPMorgan Chase & Co. Acquires 424,482 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)JPMorgan Chase & Co. lifted its holdings in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) (TSE:AUP) by 84.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 927,298 shares of the biotechnologyApril 17, 2025 | marketbeat.comWellington Management Group LLP Takes $546,000 Position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)Wellington Management Group LLP bought a new position in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) (TSE:AUP) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund bought 60,751 shares of the biotechnology company's stock, valued at aApril 16, 2025 | marketbeat.comExodusPoint Capital Management LP Buys New Shares in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)ExodusPoint Capital Management LP purchased a new position in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) (TSE:AUP) in the fourth quarter, according to its most recent filing with the SEC. The firm purchased 53,500 shares of the biotechnology company's stock, valued at approxApril 15, 2025 | marketbeat.comAmerican Century Companies Inc. Has $1.54 Million Holdings in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)American Century Companies Inc. lifted its stake in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) (TSE:AUP) by 124.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 171,590 sharesApril 12, 2025 | marketbeat.comCapula Management Ltd Purchases Shares of 35,670 Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)Capula Management Ltd acquired a new position in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) (TSE:AUP) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 35,670 shares of the biotechnology company's stock, valued at apprApril 10, 2025 | marketbeat.comArrowstreet Capital Limited Partnership Invests $9.66 Million in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)Arrowstreet Capital Limited Partnership bought a new stake in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) (TSE:AUP) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 1,075,911 shares of theApril 8, 2025 | marketbeat.comTrexquant Investment LP Has $3.97 Million Holdings in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)Trexquant Investment LP trimmed its holdings in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) (TSE:AUP) by 24.2% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 442,018 shares of theApril 7, 2025 | marketbeat.comDeclining Stock and Decent Financials: Is The Market Wrong About Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)?April 2, 2025 | finance.yahoo.comSegall Bryant & Hamill LLC Decreases Stock Holdings in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)Segall Bryant & Hamill LLC lowered its stake in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) (TSE:AUP) by 8.2% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 516,877 shares of the biotechnology company's stockMarch 29, 2025 | marketbeat.comAurinia Pharmaceuticals (NASDAQ:AUPH) Raised to "Strong-Buy" at StockNews.comStockNews.com raised Aurinia Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Thursday.March 28, 2025 | marketbeat.comCharles Schwab Investment Management Inc. Has $5.97 Million Stock Position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)Charles Schwab Investment Management Inc. cut its position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) (TSE:AUP) by 10.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 665,087 shares of thMarch 25, 2025 | marketbeat.comConnor Clark & Lunn Investment Management Ltd. Buys 102,195 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)Connor Clark & Lunn Investment Management Ltd. increased its stake in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) (TSE:AUP) by 22.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 556,454 shares of the biotechnMarch 17, 2025 | marketbeat.comInsiders Are Loading Up on These 4 Biotech Stocks NowMarch 11, 2025 | 247wallst.comAurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Insider Sells $68,350.15 in StockAurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Get Free Report) (TSE:AUP) insider Greg Keenan sold 8,305 shares of the stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $8.23, for a total value of $68,350.15. Following the completion of the sale, the insider now owns 153,484 shares of the company's stock, valued at $1,263,173.32. This trade represents a 5.13 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.March 8, 2025 | marketbeat.comGreg Keenan Sells 8,305 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) StockMarch 8, 2025 | insidertrades.comAurinia Pharmaceuticals (NASDAQ:AUPH) Shares Up 7.1% - Time to Buy?Aurinia Pharmaceuticals (NASDAQ:AUPH) Trading Up 7.1% - Here's What HappenedMarch 6, 2025 | marketbeat.comAurinia Pharmaceuticals' (NASDAQ:AUPH) Earnings May Just Be The Starting PointMarch 6, 2025 | finance.yahoo.comAurinia Pharmaceuticals Inc. (NASDAQ:AUPH) CEO Peter Greenleaf Sells 195,593 SharesAurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Get Free Report) (TSE:AUP) CEO Peter Greenleaf sold 195,593 shares of Aurinia Pharmaceuticals stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $8.00, for a total transaction of $1,564,744.00. Following the sale, the chief executive officer now directly owns 1,953,892 shares in the company, valued at approximately $15,631,136. This trade represents a 9.10 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.March 6, 2025 | marketbeat.comInsider Selling: Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Insider Sells 12,239 Shares of StockAurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Get Free Report) (TSE:AUP) insider Greg Keenan sold 12,239 shares of the firm's stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $8.00, for a total value of $97,912.00. Following the transaction, the insider now directly owns 161,789 shares of the company's stock, valued at approximately $1,294,312. This represents a 7.03 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.March 5, 2025 | marketbeat.comAurinia Pharmaceuticals Inc. (NASDAQ:AUPH) CFO Joseph M. Miller Sells 61,859 SharesAurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Get Free Report) (TSE:AUP) CFO Joseph M. Miller sold 61,859 shares of the stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $8.00, for a total transaction of $494,872.00. Following the transaction, the chief financial officer now directly owns 633,515 shares in the company, valued at $5,068,120. This trade represents a 8.90 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.March 5, 2025 | marketbeat.comInsider Selling: Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) COO Sells 65,902 Shares of StockAurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Get Free Report) (TSE:AUP) COO Matthew Maxwell Donley sold 65,902 shares of the firm's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $8.00, for a total transaction of $527,216.00. Following the completion of the transaction, the chief operating officer now directly owns 739,456 shares in the company, valued at approximately $5,915,648. The trade was a 8.18 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.March 5, 2025 | marketbeat.comGreg Keenan Sells 12,239 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) StockMarch 5, 2025 | insidertrades.comResults: Aurinia Pharmaceuticals Inc. Exceeded Expectations And The Consensus Has Updated Its EstimatesMarch 2, 2025 | uk.finance.yahoo.com1AUPH : Autoimmune Disease-Focused Aurinia Pharmaceuticals Reports Quarterly Profit,...March 1, 2025 | benzinga.comAurinia Pharmaceuticals Inc. (AUPH) Q4 2024 Earnings Call TranscriptMarch 1, 2025 | seekingalpha.comAurinia Pharmaceuticals (NASDAQ:AUPH) Posts Earnings Results, Beats Expectations By $0.04 EPSAurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) (TSE:AUP) announced its quarterly earnings data on Thursday. The biotechnology company reported $0.09 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.05 by $0.04. Aurinia Pharmaceuticals had a negative return on equity of 4.41% and a negative net margin of 10.23%.February 28, 2025 | marketbeat.comAurinia Pharmaceuticals (NASDAQ:AUPH) Sees Strong Trading Volume Following Strong EarningsAurinia Pharmaceuticals (NASDAQ:AUPH) Sees Strong Trading Volume Following Strong EarningsFebruary 28, 2025 | marketbeat.comAurinia Pharmaceuticals Full Year 2024 Earnings: EPS Beats ExpectationsFebruary 28, 2025 | finance.yahoo.comAurinia Pharmaceuticals Inc (AUPH) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ...February 28, 2025 | finance.yahoo.comRBC Capital Reaffirms Their Buy Rating on Aurinia Pharmaceuticals (AUPH)February 28, 2025 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Altimmune (ALT), Warby Parker (WRBY)February 27, 2025 | markets.businessinsider.comAutoimmune Disease-Focused Aurinia Pharmaceuticals Reports Quarterly Profit, Revenue Outlook Below ExpectationsFebruary 27, 2025 | benzinga.comAurinia Pharmaceuticals reports Q4 EPS 1c, consensus (2c)February 27, 2025 | markets.businessinsider.comAurinia Pharmaceuticals sees 2025 revenue $250M-$260M, consensus $274.4MFebruary 27, 2025 | markets.businessinsider.comAurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2024 and Provides Update on Recent Corporate ProgressFebruary 27, 2025 | financialpost.comAurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2024 and Provides Update on Recent Corporate ProgressFebruary 27, 2025 | businesswire.comAurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Stock Holdings Increased by IFP Advisors IncIFP Advisors Inc increased its holdings in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) (TSE:AUP) by 31.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 271,132 shares of the biotechnolFebruary 26, 2025 | marketbeat.comAurinia Pharmaceuticals: There's Still Time For Sales GrowthFebruary 21, 2025 | seekingalpha.com Get Aurinia Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AUPH and its competitors with MarketBeat's FREE daily newsletter. Email Address AUPH Media Mentions By Week AUPH Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AUPH News Sentiment▼0.450.73▲Average Medical News Sentiment AUPH News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AUPH Articles This Week▼23▲AUPH Articles Average Week Get Aurinia Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AUPH and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies PCVX News RYTM News PTCT News RNA News ZLAB News RARE News ACLX News SWTX News AKRO News OGN News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AUPH) was last updated on 5/4/2025 by MarketBeat.com Staff From Our PartnersThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredWill May start the next "Great Depression?"You probably haven't heard about this yet... But this could be the biggest wealth building opportunity of t...Behind the Markets | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aurinia Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aurinia Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AUPH Stock Free AUPH Stock Alerts